Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$25.92 USD
+1.46 (5.97%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $25.92 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Celldex Therapeutics, Inc.'s return on equity, or ROE, is -27.62% compared to the ROE of the Medical - Biomedical and Genetics industry of -67.20%. While this shows that CLDX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
CLDX 25.92 +1.46(5.97%)
Will CLDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLDX
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
Other News for CLDX
Is CLDX setting up for a drop? Shooting Star Candlestick shows up after sliding 0.49%
Celldex (CLDX) Reports Promising Phase 2 Results for Barzolvolimab in CSU
Celldex’s barzo shows strong efficacy in CSU patients, says H.C. Wainwright
Celldex’s Barzolvolimab Shows Promising Efficacy in Treating Chronic Spontaneous Urticaria Across Patient Subgroups
Celldex's barzo shows strong efficacy in CSU patients, says H.C. Wainwright